INRLF (Valneva SE) Interest Expense (Positive)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

INRLF Valneva SE INRLF
52 GF Score
Price $2.62
GF Value $2.68
Valuation Fairly Valued
! 6 Warning Signs
View Full Analysis

What is Valneva SE Interest Expense (Positive)?

Interest Expense (Positive) only applies to insurance companies.

INRLF
52GF Score
Valneva SE INRLF
Interest Expense (Positive) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Valneva SE (INRLF) Overvalued in 2026?

Based on GuruFocus' analysis, Valneva SE stock appears to be undervalued. The current stock price of $2.62 is trading 2.2% below its estimated GF Value™ of $2.68. GuruFocus considers Valneva SE to be Fairly Valued.

Key valuation signals for INRLF:

  • Interest Expense (Positive):
  • GF Value™: $2.68 vs. price of $2.62 (2.2% below fair value)
  • GF Score™: 52/100 with 6 warning signs

No single metric tells the full story. See the INRLF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Valneva SE Business Description

Address 12 ter Quai Perrache, Bureaux Convergence, Bat. A, Ilot Saint-Joseph, Lyon, FRA, 69002
Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates majority of its revenue from product sales.
52GF Score

Get the complete analysis for INRLF

Interest Expense (Positive) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.62
Price
$2.68
GF Value